Tesamorelin / CJC-1295 (No DAC)/ Ipamorelin Blend – 6/3/3mg

Researchers who buy this Tesamorelin / CJC-1295 (No DAC) / Ipamorelin research peptide blend are typically studying multi-mechanism growth-hormone-axis signaling — combining two structurally distinct GHRH-receptor agonists with a selective ghrelin-receptor (GHS-R1a) agonist in a single fixed-ratio preparation. Each compound is independently well-characterized in the published literature; the summary below covers each component and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.

In this reference:

• What Is This Blend?
• Tesamorelin: Mechanism and Research
• CJC-1295 (No DAC): Mechanism and Research
• Ipamorelin: Mechanism and Research
• Why Researchers Study This Combination
• Chemical Identity
• Purity, Storage & Quality
• Frequently Asked Questions

What Is This Blend?

This vial supplies a fixed-ratio, 6mg/3mg/3mg lyophilized combination of three distinct growth-hormone-axis research peptides: Tesamorelin, an extended-stability GHRH analog; CJC-1295 (without DAC), a shorter-acting GHRH analog; and Ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. All three compounds are independently well-characterized in the published pharmacology literature. Combining two GHRH-analog variants with a GHS-R1a agonist lets researchers model comparative GHRH-analog kinetics alongside dual-receptor GH-axis engagement in a single protocol.

Tesamorelin: Mechanism and Research

Tesamorelin is a synthetic GHRH-analog research peptide modified from the native GHRH(1-44) sequence to resist enzymatic degradation. A pharmaceutical-grade formulation (Egrifta/Egrifta SV) is FDA-approved for a narrow indication — reduction of excess abdominal fat in HIV-associated lipodystrophy — supported by a pivotal randomized controlled trial (Falutz J, et al., N Engl J Med. 2007;357(23):2359-2370; PMID 18057338) and a 2026 meta-analysis of five RCTs (PMID 41545261). Full detail is available on its own dedicated page: Tesamorelin. That approval history applies to a distinct pharmaceutical formulation only — not to the research-grade material in this blend.

CJC-1295 (No DAC): Mechanism and Research

CJC-1295 is a synthetic analog of the first 29 residues of native GHRH, modified for improved resistance to enzymatic degradation relative to unmodified fragments such as Sermorelin. A randomized, placebo-controlled ascending-dose trial in healthy adults reported dose-dependent increases in plasma GH (2- to 10-fold, sustained 6+ days) and IGF-1 (1.5- to 3-fold, sustained 9-11 days) following a single injection (Teichman SL, et al., J Clin Endocrinol Metab. 2006;91(3):799-805; PMID 16352683). This blend uses CJC-1295 without DAC (drug affinity complex) — the shorter-acting variant, as distinct from the albumin-binding, extended-half-life DAC variant.

Ipamorelin: Mechanism and Research

Ipamorelin is a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a), characterized as the most receptor-selective compound in its class, activating GH-axis signaling with minimal corresponding elevation of ACTH, cortisol, or prolactin in tested animal models (Raun K, et al., Eur J Endocrinol. 1998;139(5):552-561; PMID 9849822). A full literature review, including the one controlled human trial in which it has been studied (PMID 25331030), is available on its own dedicated page: Ipamorelin – 10mg.

Why Researchers Study This Combination

This three-compound blend lets researchers study two structurally distinct GHRH-receptor agonists (Tesamorelin and CJC-1295, differing in half-life and stability engineering) alongside a separate-receptor ghrelin-pathway agonist (Ipamorelin) in a single preparation. Published pharmacology treats GHRH-receptor and GHS-R1a engagement as non-redundant mechanisms, and researchers studying comparative GHRH-analog kinetics together with combined-receptor GH-axis stimulation are the typical audience for this triple-compound preparation. No published research has evaluated this specific three-compound fixed-ratio combination directly — the citations above describe each individual compound.

Chemical Identity

Purity, Storage & Quality

First Class Science supplies this triple blend at research-grade purity, with each component independently verified by third-party HPLC testing and mass spectrometry prior to blending. A Certificate of Analysis is available for every batch at our Certificate of Analysis page.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Related Preparations

Laboratories designing protocols that isolate a single mechanism typically select a standalone Tesamorelin or Ipamorelin vial, or a two-compound CJC-1295 / Ipamorelin or Tesamorelin / Ipamorelin blend.

Frequently Asked Questions

What is the purity of this blend?
Each component is independently verified via third-party HPLC and mass-spectrometry testing prior to blending, with a Certificate of Analysis published for each lot.

How should this triple blend be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is this blend approved for human or animal use?
No. A distinct pharmaceutical-grade Tesamorelin formulation (Egrifta) is FDA-approved for a specific indication, but that approval does not extend to this research-grade blend. Neither CJC-1295 nor Ipamorelin is an FDA-approved drug for any indication. This product is sold exclusively for in vitro and laboratory research use.

Why are these three specific compounds combined?
Tesamorelin and CJC-1295 are both GHRH-receptor agonists with different stability profiles; Ipamorelin is a separate-receptor GHS-R1a agonist. Researchers use this combination to study comparative GHRH-analog kinetics alongside dual-receptor GH-axis stimulation.

Has each compound been tested in humans?
Yes, independently. Tesamorelin (as its approved pharmaceutical formulation) was evaluated in PMID 18057338 and PMID 41545261. CJC-1295 was evaluated in a healthy-adult ascending-dose trial (PMID 16352683). Ipamorelin was evaluated in a narrow phase 2 trial (PMID 25331030). No trial has evaluated this specific three-compound combination.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date for each component.

Shipping, Handling & Compliance

This blend ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or controlled clinical-trial contexts, examining each individual compound. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal. No published research has evaluated this specific fixed-ratio combination directly.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.